Rethinking Cataract Surgery With Unity CS : A New Era in Phaco

Early UNITY CS users discuss how 4D phaco, Intelligent fluidics, physiologic IOP, and workflow efficiencies are changing the cataract surgery experience.

Rosa Braga-Mele, MD, FRCS (Co-Moderator); Alan R. Faulkner, MD; Michael Greenwood, MD; Arjan Hura, MD; Matthew P. Rauen, MD; Lawrence Woodard, MD (CO-moderator)

Cataract and Refractive Surgery Today

A Surprise Reversal of AMD Progression

The outer retinal layer may be key to the development of atrophy in AMD.

Talisa E. De Carlo Forest, MD

Retina Today

A 73-year-old woman with intermediate AMD presented with a subfoveal drusenoid pigment epithelial detachment (PED) with a hypertransmission defect on OCT and a VA of 20/40 OS (Figure 1). At a 6-month follow-up appointment, the drusenoid PED was collapsing, and her VA had worsened to 20/80 OS. Six months later, retinal pigment epithelium (RPE) and ellipsoid zone (EZ) atrophy of > 250 µm was noted with intact overlying outer retina, and a VA of 20/125 OS. However, 6 months later, the RPE had reformed, the EZ was recovering, the hypertransmission defect had resolved, and VA improved to 20/80 OS. Fundus imaging demonstrated early atrophy that seemed to resolve over time (Figure 2). Her VA gradually improved to 20/20 OS 3 years later with overall improvement in OCT layers and no choroidal neovascularization on OCT angiography. Of note, the patient did not receive AMD treatment, nor did she experience any change in her medical history. It’s worth noting that although anticomplement therapy may have been reasonable, the patient did not yet met the criteria for geographic atrophy. THE ROLE OF THE OUTER RETINAL LAYER The classification of atrophy meetings (CAM) criteria describe precursor stages for inevitable geographic atrophy development.1,2 The present case, in which the outer retinal layer appeared unaffected while the RPE and EZ were disrupted, did not fit into the CAM classification. The maintenance of the outer retinal layer implies that the photoreceptor cells were possibly still viable.

Pearls for iTrack Canaloplasty With Goniotomy and iDose TR Implantation

I. Paul Singh, MD

Eyetube

In this case, a patient with glaucoma who had not undergone MIGS remained on three topical medications despite prior cataract surgery and selective laser trabeculoplasty. I. Paul Singh, MD, demonstrates canaloplasty with the iTrack (Nova Eye Medical), goniotomy, and implantation of the iDose TR (Glaukos), followed by insertion of Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix).

Featured Podcasts

Ophthalmology off the Grid

Open. Outspoken. It's Ophthalmology off the Grid—an honest look at controversial topics in the field.

View Feed

New Retina Radio

New Retina Radio is a place to hear stories about retina that are told nowhere else.

View Feed

Eyewire News: The Podcast

Get the latest information and breaking news in the ophthalmic field.

View Feed

EyewireTV

10.28.2026

10.28.2026

Alcon

Johnson & Johnson

Zeiss

Glaukos

Iantrek

RxSight

Oculis

SpyGlass Pharma

Aurion Biotech

Polyactiva

OKYO Pharma

Eyewire News

Hundred Vision Launches Luma Eye-Tracking System to Assess Oculomotor and Binocular Visual Function

Johnson & Johnson Announces Global Commitment to Expand Access to Eye Care and Prevent Vision Loss

Eyedaptic Launches AI-Powered Visual Assistant for EYE7 Smart Glasses

Stocks

Cataract

Complex Exchange

Modern Thinking for Modern IOL Technology: Rethinking Full-Range Vision, Patient Selection, and Residual Astigmatism

Traumatic Iridodialysis and Aphakia

Finding the Right Fit in Ophthalmology Residency

SmartSight NOVA with CenTrax – Intelligent Centration and Eye Tracking for a New Standard of Precision

How Do Different IOL Categories Tolerate Residual Astigmatism?

11.02.2026

Hundred Vision Launches Luma Eye-Tracking System to Assess Oculomotor and Binocular Visual Function

10.30.2026

Lenz Therapeutics Announces Major Restructuring and CEO Transition

10.28.2026

Centre for Sight Founder Sheraz Daya, MD, Receives AAO Lifetime Achievement Honor Award

10.26.2026

Study Evaluates Sierra Leone’s Cataract Outreach Program

Refractive

Breaking News From the AAO Annual Meeting in New Orleans (Part 1 of 2)

Rethinking Cataract Surgery With Unity CS : A New Era in Phaco

Breaking News From the AAO Annual Meeting in New Orleans (Part 2 of 2)

Kodiak Plans to Submit BLA for Zenkuda After Phase 3 Data

Finding the Right Fit in Ophthalmology Residency

How Do Different IOL Categories Tolerate Residual Astigmatism?

11.02.2026

Hundred Vision Launches Luma Eye-Tracking System to Assess Oculomotor and Binocular Visual Function

10.30.2026

Lenz Therapeutics Announces Major Restructuring and CEO Transition

10.28.2026

Centre for Sight Founder Sheraz Daya, MD, Receives AAO Lifetime Achievement Honor Award

10.19.2026

FDA Approves Ryzumvi for the Treatment of Presbyopia

Stay Updated

Follow Eyewire News

Retina

A Surprise Reversal of AMD Progression

Breaking News From the AAO Annual Meeting in New Orleans (Part 1 of 2)

AAO '26: Fluid Debates in Wet AMD + OTX-TKI for Wet AMD

Breaking News From the AAO Annual Meeting in New Orleans (Part 2 of 2)

AAO '26: BRUNELLO and LUGANO

Sub-ILM Hemorrhage in the Macula

11.02.2026

FDA Approves Lucamzi as Ranibizumab Biosimilar to Lucentis for Retinal Diseases

11.02.2026

OpZira Completes Stage II Audit for AdaptDx Pro, Advances Plans for European CE Marking

10.30.2026

Octant Receives FDA Orphan Drug Designation for OCT-980 for the Treatment of Retinitis Pigmentosa

10.30.2026

VisioSurgical Solutions Begins Development of Compact Surgical Robot for Retinal Surgery

Glaucoma

Pearls for iTrack Canaloplasty With Goniotomy and iDose TR Implantation

Toric IOLs: When and When Not to Use in Glaucomatous Eyes

Using Imaging to Understand the Causes and Sequelae of Hypotony

The Role of MIGS in Primary Angle-Closure Glaucoma

Hands-Free Gonioscopy During iStent infinite and iDose TR Implantation

Multifocal and EDOF IOLs: My Rationale for Use in Patients With Glaucoma

10.30.2026

Lenz Therapeutics Announces Major Restructuring and CEO Transition

10.27.2026

Medicare Payment for Balance Ophthalmics’ FSYX

10.26.2026

Research Identifies Previously Unrecognized Outflow Pathway

10.22.2026